Search

Your search keyword '"Park-Simon, T.-W."' showing total 184 results

Search Constraints

Start Over You searched for: Author "Park-Simon, T.-W." Remove constraint Author: "Park-Simon, T.-W."
184 results on '"Park-Simon, T.-W."'

Search Results

1. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

Catalog

Books, media, physical & digital resources

3. Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry

4. Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival.

5. Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel

6. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

7. 208P Clinical characteristics and prognostic factors in patients with breast cancer and leptomeningeal metastases: A subanalysis of the German brain metastases in breast cancer registry (BMBC)

9. 203P Clinical effectiveness of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer (mBC) by ER expression level: Subgroup analysis from phase IIIb LUCY trial

10. Epitheliales Ovarialkarzinom

11. Chemotherapy-induced mutations in genes of clonal hematopoiesis increase the risk of myeloid neoplasms

12. 269P Long-term survival of HER2-positive breast cancer patients with brain metastases: Subanalysis of the BMBC registry

13. Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers.

14. Common variants in breast cancer risk loci predispose to distinct tumor subtypes

15. Rare germline copy number variants (CNVs) and breast cancer risk

16. Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes

17. Incorporating progesterone receptor expression into the PREDICT breast prognostic model

18. Common variants in breast cancer risk loci predispose to distinct tumor subtypes

19. Rare germline copy number variants (CNVs) and breast cancer risk

20. Chemotherapy-induced mutations in genes of clonal hematopoiesis increase the risk of myeloid neoplasms

21. Long-term survival of HER2-positive breast cancer patients with brain metastases: Subanalysis of the BMBC registry

22. Long-term survival of breast cancer patients with brain metastases: Subanalysis of the BMBC registry

23. Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial

24. Long-term survival of breast cancer patients with brain metastases: subanalysis of the BMBC Registry

25. 170P Long-term survival of breast cancer patients with brain metastases: Subanalysis of the BMBC registry

26. 174P Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: Phase IIIb LUCY final analysis

28. CYP3A7*1C allele:linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers

29. Mendelian randomisation study of smoking exposure in relation to breast cancer risk

30. 304P Incidence and resolution of eribulin-induced peripheral neuropathy (IRENE) in patients with locally advanced or metastatic breast cancer

31. Common variants in breast cancer risk loci predispose to distinct tumor subtypes

32. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

33. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

34. Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (Nature Communications, (2021), 12, 1, (1078), 10.1038/s41467-020-20496-3).

35. Breast cancer risk factors and survival by tumor subtype: Pooled analyses from the breast cancer association consortium.

36. Mendelian randomisation study of smoking exposure in relation to breast cancer risk.

37. Breast cancer risk genes - Association analysis in more than 113,000 women.

38. Erratum: Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (Nature communications (2021) 12 1 (1078)).

39. Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element.

40. CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers.

41. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.

42. Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment.

43. Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis.

44. Characteristics of patients with brain metastases from HER2-positive breast cancer

45. Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium

46. Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis

47. Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment

48. CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers

49. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (vol 12, 1078, 2021)

50. Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element